公司資料
Integra LifeSciences 股價、新聞與催化劑
- 股票代碼:
- IART
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
17.66 USD (-3.71%)
收盤價
最後更新: 2026年8月17日
1.22B USD
市值
股價為何變動
As of Aug 17, 2026, IART closed down 3.71% at $17.66. No new same-company headline was identified in the current news window.
公司概覽
Medical Technology Portfolio
Integra LifeSciences develops medical technologies used in neurosurgery, reconstructive surgery and wound care. Its products support procedures in which tissue protection, repair and regeneration are critical to patient outcomes.
Neurosurgical Technologies
The company supplies instruments, implants and systems used in neurosurgery and neurocritical care. These products include technologies for dural repair, intracranial pressure management, tissue ablation and precision surgical access.
Tissue and Wound Reconstruction
Integra’s regenerative-tissue portfolio includes products used for soft-tissue reinforcement, wound closure and surgical reconstruction. SurgiMend is a biologic matrix intended to return to production from the company’s Braintree manufacturing facility.
未來催化劑
- Start of SurgiMend production at the Braintree facility targeted by the end of June 2026.
- Relaunch of SurgiMend expected in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。